ETV Bharat / international

WHO warns against using hydroxychloroquine outside clinical trials

By

Published : May 21, 2020, 11:06 AM IST

|

Updated : May 21, 2020, 12:46 PM IST

Dr Michael Ryan, executive director of the WHO Health Emergencies Programme told that despite that both hydroxychloroquine and chloroquine are already licensed for many diseases, at this stage, they have been as yet found to be effective in the treatment of COVID-19 or in the prophylaxis against coming down with the disease.

Representative Image

Representative Image

Geneva: A senior official of the World Health Organization (WHO) has warned against using hydroxychloroquine or chloroquine, the drugs for malaria and other diseases, in the treatment of COVID-19, saying these drugs should be reserved for use within clinical trials.

Responding to question on hydroxychloroquine or chloroquine being used to treat COVID-19 patients in certain countries, Dr. Michael Ryan, executive director of the WHO Health Emergencies Programme, told a press conference on Wednesday that, despite that, both drugs are already licensed for many diseases, at this stage, they have been as yet found to be effective in the treatment of COVID-19 or in the prophylaxis against coming down with the disease, Xinhua reported.

The World Health Organisation on Wednesday warned against the use of the malaria drug hydroxychloroquine to tackle COVID-19 saying the drug had yet to be found effective in both the treatment and prophylaxis of the disease.

"And the opposite, warnings have been issued by many authorities regarding the potential side effects of the drug and many countries have limited its use to that of clinical trials or during clinical trials or under the supervision of clinicians in a hospital setting that's specifically for COVID-19, because of several potential side effects that have occurred and could occur," Ryan stressed.

Read | Trump says he's taking malaria drug to protect against virus

"Having said that, again it is for each national authority to weigh and assess the evidence for and against the use of this drug," he added.

Ryan said that hydroxychloroquine and chloroquine are included in the ongoing solidarity trials that take place across multiple countries. And as WHO, we would advise that, for COVID-19, that these drugs be reserved for use within such trials.

Dr. Maria Van Kerkhove, technical lead of Health Emergencies Programme, noted that as of today, we have more than 3,000 patients enrolled from 320 hospitals in 17 countries and so that's a show of solidarity and called the solidarity trial, but it's a show of collaboration and willingness to work towards a common goal of understanding which therapeutics are safe and effective against COVID-19.

(IANS)

Geneva: A senior official of the World Health Organization (WHO) has warned against using hydroxychloroquine or chloroquine, the drugs for malaria and other diseases, in the treatment of COVID-19, saying these drugs should be reserved for use within clinical trials.

Responding to question on hydroxychloroquine or chloroquine being used to treat COVID-19 patients in certain countries, Dr. Michael Ryan, executive director of the WHO Health Emergencies Programme, told a press conference on Wednesday that, despite that, both drugs are already licensed for many diseases, at this stage, they have been as yet found to be effective in the treatment of COVID-19 or in the prophylaxis against coming down with the disease, Xinhua reported.

The World Health Organisation on Wednesday warned against the use of the malaria drug hydroxychloroquine to tackle COVID-19 saying the drug had yet to be found effective in both the treatment and prophylaxis of the disease.

"And the opposite, warnings have been issued by many authorities regarding the potential side effects of the drug and many countries have limited its use to that of clinical trials or during clinical trials or under the supervision of clinicians in a hospital setting that's specifically for COVID-19, because of several potential side effects that have occurred and could occur," Ryan stressed.

Read | Trump says he's taking malaria drug to protect against virus

"Having said that, again it is for each national authority to weigh and assess the evidence for and against the use of this drug," he added.

Ryan said that hydroxychloroquine and chloroquine are included in the ongoing solidarity trials that take place across multiple countries. And as WHO, we would advise that, for COVID-19, that these drugs be reserved for use within such trials.

Dr. Maria Van Kerkhove, technical lead of Health Emergencies Programme, noted that as of today, we have more than 3,000 patients enrolled from 320 hospitals in 17 countries and so that's a show of solidarity and called the solidarity trial, but it's a show of collaboration and willingness to work towards a common goal of understanding which therapeutics are safe and effective against COVID-19.

(IANS)

Last Updated : May 21, 2020, 12:46 PM IST

TAGGED:

hydroxychloroquine for coronavirus

clinical trials

health emergencies programme

Copyright © 2024 Ushodaya Enterprises Pvt. Ltd., All Rights Reserved.